DK3294893T3 - Bioproduktion af lentivirale vektorer - Google Patents

Bioproduktion af lentivirale vektorer Download PDF

Info

Publication number
DK3294893T3
DK3294893T3 DK16724811.1T DK16724811T DK3294893T3 DK 3294893 T3 DK3294893 T3 DK 3294893T3 DK 16724811 T DK16724811 T DK 16724811T DK 3294893 T3 DK3294893 T3 DK 3294893T3
Authority
DK
Denmark
Prior art keywords
bioproduction
lentiviral vectors
lentiviral
vectors
Prior art date
Application number
DK16724811.1T
Other languages
English (en)
Inventor
Chi-Lin Lee
Jeffrey S Bartlett
Original Assignee
Csl Behring Gene Therapy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gene Therapy Inc filed Critical Csl Behring Gene Therapy Inc
Application granted granted Critical
Publication of DK3294893T3 publication Critical patent/DK3294893T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/70Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/40Vector systems having a special element relevant for transcription being an insulator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16724811.1T 2015-05-13 2016-05-12 Bioproduktion af lentivirale vektorer DK3294893T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161152P 2015-05-13 2015-05-13
US201562161133P 2015-05-13 2015-05-13
PCT/US2016/031959 WO2016183260A1 (en) 2015-05-13 2016-05-12 Bio-production of lentiviral vectors

Publications (1)

Publication Number Publication Date
DK3294893T3 true DK3294893T3 (da) 2024-03-04

Family

ID=56072458

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16724811.1T DK3294893T3 (da) 2015-05-13 2016-05-12 Bioproduktion af lentivirale vektorer

Country Status (13)

Country Link
US (3) US10138495B2 (da)
EP (2) EP3294893B1 (da)
JP (2) JP6975643B2 (da)
KR (1) KR20180002795A (da)
CN (1) CN107660231A (da)
AU (2) AU2016261864B2 (da)
CA (1) CA2985828C (da)
DK (1) DK3294893T3 (da)
ES (1) ES2973118T3 (da)
HK (1) HK1243730A1 (da)
PL (1) PL3294893T3 (da)
RU (1) RU2729385C2 (da)
WO (1) WO2016183260A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294893T3 (pl) * 2015-05-13 2024-04-29 Csl Behring Gene Therapy, Inc. Bioprodukcja wektorów lentiwirusowych
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
JP7470119B2 (ja) * 2018-08-24 2024-04-17 シーエスエル ベーリング ジーン セラピー インコーポレイテッド 無血清培地におけるベクター産生
EP3897745A1 (en) 2018-12-23 2021-10-27 CSL Behring LLC Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
CA3217247A1 (en) 2021-04-26 2022-11-03 Csl Behring L.L.C. Lentiviral vectors useful for the treatment of disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181353A4 (en) * 1999-05-25 2002-07-17 Univ New Jersey Med INDUCTIBLE PACKAGING CELL LINES FOR THE PRODUCTION OF LENTIVIRAL VECTORS
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
JP2006050956A (ja) * 2004-08-11 2006-02-23 Japan Science & Technology Agency プルキンエ細胞における遺伝子の発現のための発現ベクター
WO2007018318A1 (ja) * 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び/又は籠細胞特異的な遺伝子発現方法
WO2007105744A1 (ja) * 2006-03-08 2007-09-20 National University Corporation Kanazawa University プルキンエ細胞指向性ウイルスベクター
KR20090101490A (ko) * 2007-01-12 2009-09-28 더 유니버시티 오브 웨스턴 온타리오 Hiv 복합 백신 및 프라임 부스트 방법
WO2010075956A1 (de) * 2008-12-16 2010-07-08 C-Lecta Gmbh Expressionsvektor
RU2562868C2 (ru) 2009-07-15 2015-09-10 Кэлиммьюн Инк. Двойной вектор для подавления вируса иммунодефицита человека
JP2014509841A (ja) * 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
EP2782997B1 (en) 2011-11-24 2018-01-10 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
GB201202516D0 (en) * 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
JP2013208107A (ja) * 2012-03-02 2013-10-10 Takara Bio Inc レトロウイルスベクターの製造方法
WO2014099671A1 (en) * 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014200557A1 (en) * 2013-06-10 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of increasing the amount of fetal hemoglobin in a cell and/or mammal
PL3294893T3 (pl) * 2015-05-13 2024-04-29 Csl Behring Gene Therapy, Inc. Bioprodukcja wektorów lentiwirusowych

Also Published As

Publication number Publication date
RU2729385C2 (ru) 2020-08-06
HK1243730A1 (zh) 2018-07-20
RU2017143141A3 (da) 2019-11-26
JP6975643B2 (ja) 2021-12-01
JP7469280B2 (ja) 2024-04-16
EP4316500A2 (en) 2024-02-07
AU2016261864A1 (en) 2017-11-23
EP4316500A3 (en) 2024-04-10
KR20180002795A (ko) 2018-01-08
US10138495B2 (en) 2018-11-27
EP3294893A1 (en) 2018-03-21
US20220315950A1 (en) 2022-10-06
WO2016183260A1 (en) 2016-11-17
PL3294893T3 (pl) 2024-04-29
US20190085359A1 (en) 2019-03-21
AU2016261864B2 (en) 2022-05-26
JP2018516557A (ja) 2018-06-28
RU2017143141A (ru) 2019-06-13
JP2022043022A (ja) 2022-03-15
AU2022218478A1 (en) 2022-09-08
ES2973118T3 (es) 2024-06-18
CN107660231A (zh) 2018-02-02
US20180112233A1 (en) 2018-04-26
CA2985828C (en) 2020-07-14
US11299752B2 (en) 2022-04-12
EP3294893B1 (en) 2023-12-27
CA2985828A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3145949T3 (da) Lentivirale vektorer
DK3180331T3 (da) Polymorfer af selinexor
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3117030T3 (da) Diagnosticering af sepsis
DK3473263T3 (da) Kombinerede præparater til behandling af kræft
DK3514109T3 (da) Hydropyrolyse af biomasseholdige råmaterialer
DK3307267T3 (da) Behandling af multipel sklerose
DK3294893T3 (da) Bioproduktion af lentivirale vektorer
DK3283210T3 (da) Fremgangsmåde
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3201323T3 (da) Modificering af bakteriofag
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3113773T3 (da) Krystallinske former af grapiprant
NO2023044I1 (no) capromorelin
DK3418273T3 (da) Derivater af flavagliner
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3173071T3 (da) Formularing af maropitant
DK3200783T3 (da) Behandling af erytromelalgi
DK3183359T3 (da) Effektiv valg af rekombinante proteiner